IP Library Granted Patent US 6,849,720
Granted Patent B2
US 6,849,720 · App. 10/221,679 · Granted Feb 1, 2005

Monoclonal antibodies to the human LDL receptor, their production and use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,849,720
App. No.
10/221,679
Granted
Feb 1, 2005
Kind
B2
Abstract

There are provided monoclonal antibodies to the LDL receptor which are useful for the identification and purification of LDL and in treatment of e.g. hepatitis C infection.

Claims (13)

1. A monoclonal antibody expressed by hybridoma clone 12.6 deposited at the CNCM under No.1-2390.

2. A monoclonal expressed by hybridoma clone 28 deposited at the CNCM under No. I-2391.

3. A monoclonal antibody expressed by hybridoma clone 29.8 deposited at the CNCM under No. I-2392.

4. A monoclonal antibody expressed by hybridoma clone 30 deposited at the CNCM under No. I-2393.

5. A monoclonal antibody expressed by hybridoma clone 50.30 deposited at the CNCM under No. I-2394.

6. A hybridoma clone 12.6 deposited at the CNCM under No.1-2390.

7. A hybridoma clone 28 deposited at the CNCM under No.1-2391.

8. A hybridoma clone 29.8 deposited at the CNCM under No.1-2392.

9. A hybridoma clone 30 deposited at the CNCM under No.1-2393.

10. A hybridoma clone 50.30 deposited at the CNCM under No. I-2394.

11. A method for purifying human low-density receptor (LDLR) which comprises contacting a material containing crude human LDLR with the monoclonal antibody according to any one of claims 1 - 5 to affinity purify human LDLR.

12. A method for neutralizing an antiviral biological activity of recombinant human soluble low-density lipoprotein receptor (r-hsLDLR) comprising contacting r-hsLDLR with the monoclonal antibody of claim 1 or 5 to neutralize an antiviral biological activity of r-hsLDLR.

13. A method for inhibiting replication of hepatitis C virus, comprising contacting cells with the monoclonal antibody of claim 1 , 2 or 3 prior to infection by hepatitis C virus to inhibit replication of hepatitis C in the cells.

Assignments (3)
CHANGE OF NAME Recorded Nov 25, 2009
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 023569/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2007
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 019966/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2003
From: YONAH, NACHUM; SUISSA, DANY; BELZER, ILANA; ANTONETTI, FRANCESCO; SMOLARSKY, MOSHE; DREANO, MICHEL
To: APPLIED RESEARCH SYSTEMS ARS HOLDING, N.V.
Reel/Frame 014393/0668 →